The following is a list of antibiotics. The highest division between antibiotics is bactericidal and bacteriostatic. Bactericidals kill bacteria directly, whereas bacteriostatics prevent them from dividing. However, these classifications are based on laboratory behavior. The development of antibiotics has had a profound effect on the health of people for many years. Also, both people and animals have used antibiotics to treat infections and diseases. In practice, both treat bacterial infections.[1]
By coverage
The following are lists of antibiotics for specific microbial coverage (not an exhaustive list):
MRSA
Antibiotics that cover methicillin-resistant Staphylococcus aureus (MRSA):
Pseudomonas aeruginosa
Antibiotics that cover Pseudomonas aeruginosa:
Certain cephalosporins, cephalosporin-beta-lactamase-inhibitor combinations, and new siderophore cephalosporins.
Certain penicillins:
Certain carbapenems and carbapenem-beta-lactamase-inhibitors combinations:
Others:
VRE
Antibiotics that usually have activity against vancomycin-resistant Enterococcus (VRE):
Antibiotics with less reliable but occasional (depending on isolate and subspecies) activity:
- occasionally penicillins including penicillin, ampicillin and ampicillin-sulbactam, amoxicillin and amoxicillin-clavulnate, and piperacillin-tazobactam (not all vancomycin-resistant Enterococcus isolates are resistant to penicillin and ampicillin)
- occasionally doxycycline and minocycline
- occasionally fluoroquinolones such as moxifloxacin, levofloxacin, and ciprofloxacin
By class
See also pathogenic bacteria for a list of antibiotics sorted by target bacteria.
Note: (Bs): Bacteriostatic
Antibiotic candidates
These are antibiotic candidates, and known antibiotics that are not yet mass-produced.
See also
Notes
- ^ Note: Malaria is caused by a protist and not a bacterium.
References
- ^ Pelczar, M. J.; Chan, E. C. S. and Krieg, N. R. (1999) "Host-Parasite Interaction; Nonspecific Host Resistance", In: Microbiology Concepts and Applications, 6th ed., McGraw-Hill Inc., New York pp. 478-479.
- ^ a b c d Aoki M (2015). レジデントのための感染症診療マニュアル. Japan: 医学書院. ISBN 978-4-260-02027-5.
- ^ Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA (2008). "Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin". American Journal of Clinical Dermatology. 9 (4): 245–54. doi:10.2165/00128071-200809040-00004. PMID 18572975. S2CID 24357533.
- ^ a b c d For common Uses and possible side effects reference is: Robert Berkow (ed.) The Merck Manual of Medical Information - Home Edition. Pocket (September 1999), ISBN 0-671-02727-1.
- ^ "Neomycin Drug Information". uptodate. Retrieved November 2, 2012.(subscription required)
- ^ Berger DS (2014-04-03). GIDEON Guide to Antimicrobial Agents (2014 ed.). GIDEON Informatics Inc. p. 221. ISBN 978-1-61755-839-9. Retrieved 4 February 2015.
- ^ Splete H, Kerri Wachter (March 2006). "Liver toxicity reported with Ketek". Internal Medicine News.
- ^ McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH (March 2018). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)". Clinical Infectious Diseases. 66 (7): e1–e48. doi:10.1093/cid/cix1085. PMC 6018983. PMID 29462280.
- ^ Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T (November 2010). "A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin". Microbiology. 156 (Pt 11): 3354–9. doi:10.1099/mic.0.042010-0. PMID 20724385.
- ^ a b Dificid (fidaxomicin) [prescribing information] Whitehouse Station, NJ: Merck; December 2015.
- ^ Casellas JM, Israele V, Marín M, Ishida MT, Heguilen R, Soutric J, Arenoso H, Sibbald A, Stamboulian D (September 2005). "Amoxicillin-sulbactam versus amoxicillin-clavulanic acid for the treatment of non-recurrent-acute otitis media in Argentinean children". International Journal of Pediatric Otorhinolaryngology. 69 (9): 1225–33. doi:10.1016/j.ijporl.2005.03.016. PMID 16061111.
- ^ "APO-Amoxycillin and Clavulanic Acid 500mg/125 mg Tablets" (PDF). Retrieved November 27, 2014.
- ^ Mechanism of Action of Bacitracin: Complexation with Metal Ion and C55-Isoprenyl Pyrophosphate K. John Stone and Jack L. Strominger
- ^ "List of Antibiotics". Retrieved February 7, 2014.
